Bibliography
- Bartel DP , ChenCZ: Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs.Nat. Rev. Genet.5 , 396–400 (2004).
- Filipowicz W , BhattacharyyaSN, SonenbergN: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?Nat. Rev. Genet.9 , 102–114 (2008).
- Singh SK , Pal Bhadra M, Girschick HJ, Bhadra U: MicroRNAs – micro in size but macro in function. FEBS J275 , 4929–4944 (2008).
- Calin GA , DumitruCD, ShimizuM et al.: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc. Natl Acad. Sci. USA99 , 15524–15529 (2002).
- Murakami Y , YasudaT, SaigoK et al.: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.Oncogene25 , 2537–2545 (2006).
- Takamizawa J , KonishiH, Yanagisawa Ket al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res.64 , 3753–3756 (2004).
- Ciafre SA , GalardiS, MangiolaA et al.: Extensive modulation of a set of microRNAs in primary glioblastoma.Biochem. Biophys. Res. Commun.334 , 1351–1358 (2005).
- Fabbri M , CroceCM, CalinGA: MicroRNAs.Cancer J.14 , 1–6 (2008).
- Cobb BS , HertweckA, SmithJ et al.: A role for Dicer in immune regulation.J. Exp. Med.203 , 2519–2527 (2006).
- Ueda R , KohanbashG, SasakiK et al.: Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.Proc. Natl Acad. Sci. USA106 , 10746–10751 (2009).
Bibliography
- Smyth MJ , GodfreyDI, TrapaniJA: A fresh look at tumor immunosurveillance and immunotherapy.Nat. Immunol.2 , 293–299 (2001).
- Dong H , StromeSE, SalomaoDR et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat. Med.8 , 793–800 (2002).
- Wintterle S , SchreinerB, MitsdoerfferM et al.: Expression of the B7-relatedmolecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.Cancer Res.63 , 7462–7467 (2003).
- Parsa AT , WaldronJS, PannerA et al.: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.Nat. Med.13 , 84–88 (2007).
- Crane C , PannerA, PieperRO, ArbiserJ, ParsaAT: Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.J. Immunother.32 , 585–592 (2009).
- Powell JD , ZhengY: Dissecting the mechanism of T-cell anergy with immunophilin ligands.Curr. Opin. Investig. Drugs7 , 1002–1007 (2006).
- Kim BH , ChoJY: Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression.Acta Pharmacol. Sin.29 , 113–122 (2008).
Bibliography
- Prigent SA , NaganeM, LinH et al.: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway.J. Biol. Chem.271 , 25639–25645 (1996).
- Moscatello DK , RamirezG, WongAJ: A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.Cancer Res.57 , 1419–1424 (1997).
- Olapade-Olaopa EO , MoscatelloDK, MacKayEH et al.: Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer.Br. J. Cancer82 , 186–194 (2000).
- Wikstrand CJ , HaleLP, BatraSK et al.: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast andlung carcinomas and malignant gliomas.Cancer Res.55 , 3140–3148 (1995).
- Wu A , WiesnerS, XiaoJ et al.: Expressionof MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.J. Neurooncol.83 , 121–131 (2007).
- Bullain SS , SahinA, SzentirmaiO et al.: Genetically engineered T cells to target EGFRvIII expressing glioblastoma.J. Neurooncol.94 , 373–382 (2009).
- Marcu-Malina V , van Dorp S, Kuball J: Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert Opin. Biol. Ther.9 , 579–591 (2009).